0000950170-23-068283.txt : 20231205
0000950170-23-068283.hdr.sgml : 20231205
20231205172322
ACCESSION NUMBER: 0000950170-23-068283
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231205
DATE AS OF CHANGE: 20231205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simonian Nancy A
CENTRAL INDEX KEY: 0001359574
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37813
FILM NUMBER: 231467667
MAIL ADDRESS:
STREET 1: C/O SYROS PHARMACEUTICALS, INC.
STREET 2: 620 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001556263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453772460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-744-1340
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: LS22, Inc.
DATE OF NAME CHANGE: 20120815
4
1
ownership.xml
4
X0508
4
2023-12-01
0001556263
Syros Pharmaceuticals, Inc.
SYRS
0001359574
Simonian Nancy A
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
true
false
false
false
false
Stock Option (right to buy)
121.70
2023-12-01
4
D
false
7500
D
2026-09-15
Common Stock
7500
0
D
Stock Option (right to buy)
109
2023-12-01
4
D
false
17499
D
2027-02-09
Common Stock
17499
0
D
Stock Option (right to buy)
100.90
2023-12-01
4
D
false
28001
D
2028-02-15
Common Stock
28001
0
D
Stock Option (right to buy)
75.40
2023-12-01
4
D
false
29399
D
2030-02-12
Common Stock
29399
0
D
Stock Option (right to buy)
114.10
2023-12-01
4
D
false
30399
D
2031-02-16
Common Stock
30399
0
D
Fully vested.
The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023.
This option vested as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments thereafter through February 28, 2024.
This option vested as to 25% of the shares on February 28, 2022, with the remainder vesting in equal monthly installments thereafter through February 28, 2025.
Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
/s/ Todd Rosenthal, as attorney-in-fact
2023-12-05